Receptors for human plasminogen on the biological response modifier OK-432.
The biological response modifier OK-432, constituting cell wall fragments from a group A Streptococcus strain and used in anticancer therapy trials, was tested for its ability to interact with different plasma proteins. The uptake of 125I-labelled protein was measured using a panel of six different plasma proteins all known to react with receptors on a majority of streptococcal strains. Of the proteins tested, plasminogen demonstrated the most substantial uptake, with uptake values ranging from 70 to 79%. A slight interaction with fibrinogen was also detected whereas no significant interaction was found with either human immunoglobulin (Ig)A, IgG, serum albumin, or mouse albumin. The results with plasminogen suggest the possibility of a new explanation of the antitumor activity described for OK-432.
Ullberg
M
M
Department of Clinical Microbiology, Karolinska Hospital, Stockholm, Sweden.
Tewodros
W
W
Kronvall
G
G
D001798:Blood Proteins / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D010844:Picibanil / Q000378:metabolism*; D010958:Plasminogen / Q000378:metabolism; D011485:Protein Binding; D011956:Receptors, Cell Surface / Q000378:metabolism*; D055293:Receptors, Urokinase Plasminogen Activator; D013297:Streptococcus pyogenes / Q000378:metabolism
D001798:Blood Proteins; C524898:PLAUR protein, human; C524899:Plaur protein, mouse; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D010844:Picibanil; D010958:Plasminogen; D005341:Fibrinolysin